The first 60 days: Liposarcoma
Liposarcoma is a cancer of fat cells that comes in four different forms: two driven by extra copies of the MDM2 gene, one by a fusion gene that makes it unusually sensitive to radiotherapy and trabectedin, and one that behaves like other aggressive sarcomas. Surgery is the mainstay and MDM2 inhibitors are the most promising drugs in trials. Below, week by week, is what OnCo's record of Liposarcoma says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- SurgeonNamed in the standard of care for: Well-differentiated, limb, Retroperitoneal well- and dedifferentiated, Myxoid liposarcoma.
- Medical oncologistNamed in the standard of care for: Well-differentiated, limb, Retroperitoneal well- and dedifferentiated, Myxoid liposarcoma, Advanced disease.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Well-differentiated, limb, Retroperitoneal well- and dedifferentiated, Myxoid liposarcoma.
- Palliative and supportive care teamNamed in the standard of care for: Advanced disease.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Marginal excision; no radiotherapy or systemic therapy; surveillance for local recurrence.
Complete en bloc resection in a sarcoma centre; preoperative radiotherapy not routine after STRASS; repeat surgery for recurrence.
Surgery with preoperative radiotherapy (highly radiosensitive); trabectedin for advanced disease.
Doxorubicin-based chemotherapy, eribulin (overall survival benefit in liposarcoma), trabectedin; MDM2 and CDK4 inhibitors in trials for amplified tumours.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example MDM2 and CDK4 amplification, FUS-DDIT3 fusion, Round cell component, Grade and site), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Well-differentiated liposarcoma, Dedifferentiated liposarcoma, Myxoid and round cell liposarcoma.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Well-differentiated, limb
- For my situation (well-differentiated, limb), which of the standard options do you recommend and why?Guideline options include: Marginal excision; no radiotherapy or systemic therapy; surveillance for local recurrence.
Retroperitoneal well- and dedifferentiated
- For my situation (retroperitoneal well- and dedifferentiated), which of the standard options do you recommend and why?Guideline options include: Complete en bloc resection in a sarcoma centre; preoperative radiotherapy not routine after STRASS; repeat surgery for recurrence.
Myxoid liposarcoma
- For my situation (myxoid liposarcoma), which of the standard options do you recommend and why?Guideline options include: Surgery with preoperative radiotherapy (highly radiosensitive); trabectedin for advanced disease.
- Am I a candidate for Trabectedin, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Advanced disease
- For my situation (advanced disease), which of the standard options do you recommend and why?Guideline options include: Doxorubicin-based chemotherapy, eribulin (overall survival benefit in liposarcoma), trabectedin; MDM2 and CDK4 inhibitors in trials for amplified tumours.
- Am I a candidate for Doxorubicin, Eribulin, Trabectedin, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of MDM2 inhibitors, Eribulin?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Retroperitoneal dedifferentiated disease recurs in most patients despite complete surgery”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “MDM2 inhibitors cause low platelets that limit dosing”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Liposarcoma: the full pageLiposarcoma is a cancer of fat cells that comes in four different forms: two driven by extra copies of the MDM2 gene, one by a fusion gene that makes it unusually sensitive to radiotherapy and trabectedin, and one that behaves like other aggressive sarcomas. Surgery is the mainstay and MDM2 inhibitors are the most promising drugs in trials.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.